TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Women undergoing cesarean section delivery.~2. Patients classified as American Society of Anesthesiology (ASA) class II or III.~   1. ASA II: mild systemic disease, pregnancy~  2. ASA III: severe systemic disease~3. Women ≥ 18 years old~4. Neuraxial anesthesia (spinal) to be used as anesthetic technique intraoperatively for cesarean section (this is the UAB Anesthesiology standard of care).~Exclusion Criteria:~1. Any patient not classified as an ASA I or II.~2. General Anesthesia or neuraxial anesthesia with epidural used as anesthetic techniques for cesarean section.~3. Allergy/intolerance to local anesthetic or steroids.~4. Pre-existing neurological and/or anatomical deficit that would preclude regional block.~5. Coexisting coagulopathy such as hemophilia or von Willebrand Disease~6. BMI \> 40.~7. Emergency Cesarean Sections

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): 20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.
- 2mg Dexamethasone (Type: ACTIVE_COMPARATOR): 20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.
- 4mg Dexamethasone (Type: ACTIVE_COMPARATOR): 20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) not curable by local therapy~* No prior systemic therapy for SCCHN in the recurrent or metastatic setting (with the exception of systemic therapy completed \> 6 months prior if given as part of multimodal treatment for locally advanced disease)~* Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Patients may not have a primary tumor site of upper esophagus, salivary gland, or nasopharynx (any histology)~* Availability of formalin-fixed, paraffin embedded tumor specimen or contemporary biopsy for immunohistochemical evaluation of pharmacodynamic markers of interest~* Willing to consent for baseline and on-treatment biopsy.~* Performance status 0 or 1~* Life expectancy of 6 months or more~* Adequate end organ function~* At least one radiographically measurable lesion~* PD-L1 expression level that is either~  1. Positive (combined positive score \[CPS\] ≥ 1) for the retifanlimab cohort, or~ 2. Negative (CPS \< 1) for the tebotelimab cohort~* Results available from human papilloma virus p16 status for oropharyngeal cancer~* Acceptable laboratory results~Exclusion Criteria:~* Disease suitable for local therapy administered with curative intent~* Progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN~* Radiation or other non-systemic therapy within 2 weeks prior to the first dose of study drug~* Prior therapy with an anti-B7-H3, anti-PD-1, anti-PD-L1, or anti-LAG-3 agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Retifanlimab Cohort (Type: EXPERIMENTAL): Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles
- Tebotelimab Cohort (Type: EXPERIMENTAL): Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Detection of Bacteria in Herniated Nucleus Material in Lumbar Disc Herniations by Culture and PCR

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* MRI-confirmed lumbar disc herniation.~* Age between 18 and 65 years.~* No prior spine surgery.~* No diagnosed dementia.~Exclusion Criteria:~* Antibiotic treatment within the previous two weeks.~* History of alcohol abuse, illicit drug use or drug abuse, or significant mental illness~* Known immune deficiency state (e.g., positive for human immunodeficiency virus) or in treatment with immunosuppressive drugs including high dose steroids or cyclosporine.~* Concurrent infections (infections of skin, urinary tract infection, other skin diseases, e.g. Acne vulgaris).~* Previous epidural instrumentation.~* Uncontrolled, unstable or recently diagnosed autoimmune disease, including but not limited to systemic lupus erythematosus, inflammatory bowel disease, sarcoidosis, rheumatoid arthritis, or psoriasis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A female older than 21 years of age,~2. Have suspicious imaging findings suggesting a possibility of breast cancer, or biopsy-proven breast cancer.~Exclusion Criteria:~1. Pregnant,~2. Unwilling to give informed consent,~3. Have implanted prosthetic heart valves, pacemaker, neuro-stimulation devices, surgical clips (hemostatic clips) or other metallic implants,~4. Have engaged in occupations or activities which may cause accidental lodging of ferromagnetic materials, or have imbedded metal fragments from military activities,~5. Have received orthodontic work involving ferromagnetic materials,~6. Claustrophobic,~7. Have had allergic response to contrast agents (such as iodine or gadolinium) previously,~8. Have known history of severe renal insufficiency, asthma, allergic conditions, sickle cell anemia, chronic hemolytic anemia, and gastrointestinal disorders.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Disease Group (Type: EXPERIMENTAL): Patients with suspicious breast diseases
- Control Group (Type: EXPERIMENTAL): Healthy volunteers for system testing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Evaluation of the Effect of Riboflavin Supplementation on Blood Pressure and Possible Effect Modification by the MTHFR C677T Genotype

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy, aged between 18-70 years~* Has provided appropriate ethical consent for involvement in studies relating to genetics.~* Has available genotype data in the Keneba biobank needed for the current study~* Available for the duration of the intervention period~Exclusion Criteria:~Taking vitamin B/multivitamin supplements~* Ongoing pregnancy as confirmed by participant~* History of digestive, hepatic, renal or hematological disorders, dementia~* Epilepsy or taking anti-epileptic medications~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- treatment arm (Type: EXPERIMENTAL): 5mg Riboflavin pills
- Placebo arm (Type: PLACEBO_COMPARATOR): Placebo pills

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Flu Vaccination and Burden of Illness Among Community-dwelling Elderly With Influenza Like Illness in Brazil

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.~* A male or female \>= 65 years of age.~* Written informed consent obtained from the subject.~* Presenting within the first 72 hours of an influenza-like illness. Influenza-like illness is defined as the presence of:~  * Fever measured by the patient or physician and at least one of the following symptoms:~ * Sore throat.~ * Coryza (runny nose) and/or nasal congestion.~ * Cough.~* Availability to be followed up by phone or in person after an interval of approximately 14 - 21 days.~Exclusion Criteria:~* Receipt of any experimental influenza vaccine within 6 months of the onset of the influenza-like illness.~* Terminal stage of disease.~* Subjects living in a nursing home.~* Use of any investigational or non-registered product planned during the study period.~* Subjects who have already been enrolled in this study.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Subjects with influenza like illness

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pain, Opioids and Pro-Inflammatory Immune Responses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* male and non-pregnant female, non-smoking adults in good general health~* between the ages of 21-40 years old~* fluent in English with willingness to participate in the research study~Supplementary Inclusion Criteria: Prescription Opioid Abusers~* DSM-IVR diagnosis of prescription opioid abuse or dependence disorder~* compliance in treatment and on a stable dose of buprenorphine (6-24mg/day) x at least 10 days prior to screening~* Participation in an ISAP treatment program or a qualified community-based opioid treatment program or private clinic for the entire duration of their study participation~Exclusion criteria:~* regular use of any medication that influences immune status or immune system function~* regular use of a medication that influences pain perception, including opioids (\* only for healthy subjects population\*)~* Regular use of a medication that influences pain perception, except for buprenorphine (\*\* only for POA population\*\*)~* known hypersensitivity to opioids or no previous opioid exposure (\*only healthy controls)~* presence of acute or chronic pain syndrome~* neuropsychiatric illness (i.e., peripheral neuropathy, schizophrenia) known to affect pain perception~* presence of chronic immune compromise (hepatitis C, HIV) or acute infection within the last four weeks~* current or past history of high blood pressure, heart disease, or stroke, or currently have a pacemaker.~* current DSM-IV diagnosis~* BMI less than 18.5 or greater than 29.9~* History of sleep apnea

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Pain Challenge (Type: ACTIVE_COMPARATOR): Cold pressor test
- Pain + Opioid Challenge (Type: ACTIVE_COMPARATOR): IV fentanyl 1mcg/kg followed by cold pressor test
- Opioid Challenge (Type: ACTIVE_COMPARATOR): Administration of fentanyl 1mcg/kg of subject weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Meal Tolerance Trial in Pregnant Women Diagnosed With Gestational Diabetes Mellitus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pregnant women, aged 18-40 years~2. 18.5 kg/m2 \< pre-pregnancy BMI \< 27.5 kg/m2 \[representing low to moderate risk category, adapted from WHO expert panel recommendation on BMI categories for determining public health and clinical action (REF: Lancet, 2004)\]~3. Singleton pregnancy~4. Newly GDM diagnosed women between 24 to (the latest) 32 weeks of gestation;~5. Diagnosed GDM according to either:~   * World Health Organization (WHO) criteria if one or more glucose values equal to or exceed these threshold values \[75g Oral Glucose Tolerance Test: fasting 126 mg/dl; 2-h 140 mg/dl\] or~  * American Diabetic Association (ADA) criteria if two or more glucose values equal to or exceed these threshold values \[100g Oral Glucose Tolerance Test: fasting 95 mg/dl; 1-h 180 mg/dl; 2-h 155 mg/dl, 3-h 140/dl\]~6. Willing and able to comply with the protocol~7. Signed informed consent~Exclusion Criteria:~1. Any gastrointestinal disease that interferes with bowel function and nutritional intake (i.e. constipation or diarrhea secondary to neuropathy, diarrhea due to chronic inflammatory bowel disease, gastroparesis, gastrectomy, galactosaemia, hyperemesis)~2. Currently on anti-diabetic therapy, for example on insulin or oral anti-diabetic medication~3. Already using a diabetes nutritional/dietary supplement (e.g. Glucerna®, Nutrient Diabetes®) within 4 weeks prior to signing informed consent~4. Known allergy or intolerance for any of the following ingredients; fish, milk, protein, lactose, fiber or soy~5. Any significant medical condition, other than GDM, that might interfere with the study or known to affect intra-uterine growth (e.g. Type 1 Diabetes, Type 2 Diabetes Mellitus, Crohn's disease, HIV/AIDS, liver disease, kidney disease etc.)~6. Currently or previously on special low/no carbohydrate diet (e.g. Atkin's diet) within 8 weeks prior to signing informed consent~7. Incapability to comply with study protocol or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements~8. Participation in other studies involving investigational or marketed products concomitantly or within 4 weeks prior signing informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Test group (Type: ACTIVE_COMPARATOR): Nutritional product as breakfast.
- Control Group (Type: OTHER): Standard breakfast according to ADA recommendations for pregnant women diagnosed with Gestational Diabetes Mellitus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Fracture of Distal Radius and Ulna Healed With Shortening of One Bone. Clinical Significance at Skeletal Maturity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children that had had Ulna or Radius X-rays~* Signing Informed consent.~Exclusion Criteria:~- Unwillingness to sign informed consent.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single-Incision Laparoscopic Cholecystectomy Versus Traditional Laparoscopic Cholecystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient recommended to undergo cholecystectomy~* Patient age 18-80~* Patient competent to give his/her own informed consent~* Patient speaks English without the need for an interpreter~Exclusion Criteria:~* Additional procedures planned during same surgery~* Patient deemed inappropriate for TLC or SILS cholecystectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Single-Incision Laparoscopic Cholecsytectomy (SILS) (Type: ACTIVE_COMPARATOR): None
- Traditional Laparoscopic Cholecystectomy (TLC) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus (MRSA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must have given written informed consent~* Must be ≥ 18 years of age and not of child bearing potential~* Must have an ulcer in which the presence of MRSA has been identified, but which is not clinically infected~* Must have an ulcer size not to extend beyond the inner borders of the dressing~Exclusion Criteria:~* Is a female of child bearing years or who could become pregnant~* Is \< 18 years of age~* Has an clinically infected skin ulcer~* Has a ulcer that is being treated with a topical antimicrobial agent or has been treated with a topical antimicrobial agent during 3 days prior to enrolment~* Has been using systemic antibiotics during 7 days prior to enrolment into this study~* Has an ulcer which is identified as malignant in origin (e.g. Marjolin's ulcer)~* Has an ulcer size beyond the inner borders of the dressing~* Is septic or has other signs of an invasive infection~* Has used any investigational drug within 30 days preceding study participation.~* Suffers from a condition, which, in the opinion of the Investigator, would compromise his or her safety.~* Suffers from a condition which, in the opinion of the Investigator, would compromise the quality of the data.~* Has a known allergy to any of the products that are part of this protocol~* Suffers from a condition which, in the opinion of the Investigator, would seriously interfere negatively with the normal parameters of immune response to an infection.~* Is using any of the prohibited concomitant medications or treatments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dextrose Infusion by Burettes Versus Dextrose Boluses in Prevention of Neonatal Hypoglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- SELECTION CRITERIA Inclusion criteria~* Preterms whose care givers/ mothers gave informed consent~* Preterms whose age was \< 24 hours of life~* Preterms with birth weight ≥1kg~* Preterms with random blood sugar ≥ 2.6 mmol/l at admission into SCU.~Exclusion Criteria~* Absence of a biological mother or abandoned baby~* Presence of gross congenital abnormalities.~* Very sick (Apgar score ≤ 5 at 5 minutes

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: t

Study Arms:
- Bolus arm (Type: PLACEBO_COMPARATOR): two hourly dextrose boluses administered via an intravenous cannula
- infusion (Type: EXPERIMENTAL): 10% dextrose infusion by burettes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Brain Oxygen Tension Level and Cleaved-tau Protein to Detect Vasospasm After SAH

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with subarachnoid hemorrhage~* Patients with external ventricular drains~Exclusion Criteria:~* Patients in whom consent is not attainable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Hemorrhage (Type: None): Patients having experienced subarachnoid hemorrhage and have in place a ventriculostomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues